ArticleCardiovascular and interventional radiology2025
Segmental Yttrium-90 Radioembolization with Day-of-Calibration Resin Microspheres: Durable Transarterial Ablation for Solitary Hepatocellular Carcinoma.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High-Specific-Activity Resin Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Study of Efficacy, Safety, and Dosimetry Considerations.Cardiovascular and interventional radiology · 2026Article
- Is Radiation Segmentectomy Ready to Compete with Thermal Ablation for Early-Stage HCC?Cardiovascular and interventional radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeveral recent studies report safety and efficacy of resin yttrium-90 radiation segmentectomy for localized hepatocellular carcinoma. Data informing tumor dose, angiosome dose, and spheres/mL required for ablative-intent resin radioembolization are incomplete. The safety, efficacy, dosimetry, and explant pathology of radiation segmentectomy with day-of calibration (DOC) spheres are reported. MATERIALS AND
methodsPatients were identified at a tertiary care institution who received radiation segmentectomy with DOC resin during a 10-year period. Post-Y90 dosimetry was performed with Medical Image Merge (MIM) Software. Imaging response, 30-day toxicities, explant pathology, duration of response, and overall survival were analyzed. Associations between dosimetric variables and durable response were tested with receiver operator characteristic, Wilcoxon, and odds ratio analyses.
resultsTwenty tumors in 20 patients were treated, median size 2.6 [range 1.4-6.3] cm. Fifteen patients (75%) were male; median age 68 [range 48-88] years. Seventeen patients (85%) had Child A cirrhosis, 12 from hepatitis C; 15/20 were AlBi grade 2. Sixteen single-vessel and four double-vessel (split dose) treatments reached stasis in 17/24 (71%) infusions. Median tumor and angiosome dose were 263 [range 83-649] and 139 [31-392]. Median lowest dose to any portion of a treated tumor was 147 [29-299] Gy. Median tumor sphere concentration was 79 k [23-206 k] spheres/mL. Local modified REsponse Evaluation Criteria in Solid Tumors (mRECIST) response rates were 18 (90%) complete (16 durable), one partial response, and one stable disease. Two patients experienced adverse events: one at grade 3 and the other at grade 2. Median follow-up was 20 [range 4-126] months. Median duration of response was 47 months. Median overall survival was > / = 94 months both with and without censoring patients at transplant. All six explants demonstrated complete pathologic necrosis. Smaller tumor volume was associated with durable complete response (AUC 0.96), as was infusion to stasis (OR 18 [95% CI 1.19, 271]). Smaller tumor volume and lower angiosome dose were associated with stasis (p = 0.013, 0.035).
conclusionDay-of calibration resin segmentectomy treating to stasis is safe and may yield highly durable ablative outcomes for HCC under 3 cm diameter at lower doses than recommended for glass or pre-calibrated resin Y90. Use of more spheres or higher dose targets is likely warranted for larger tumors.
Indexed as
Identifiers
40813475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.